Australian biotech market watch 28/09/09
Monday, 28 September, 2009
The ASX200 opened sharply lower as expected, and was sitting at 4659 at 11:00am.
Among the pharmaceutical stocks, market heavyweight CSL Limited (ASX:CSL) was down 52c to $33.85
Photoprotective drug manufacturer, Clinuvel Pharmaceuticals (ASX:CUV) slumped nearly 6% to 31.5c after releasing its full year financial results – a 32% drop in revenues and a loss of $15.3M
Cellistis Limited (ASX:CST) fared little better, dropping 12c to $3.25 despite its recent announcement of a record $8.2M annual profit. The Cellistis share price had recently spiked as high as $4.00 and had more than tripled since February.
More positive numbers for Acrux (ASX:ACR) up almost 5% to $1.58 and Chemgenex (ASX:CXS) up almost 4% to 78.5c
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
